ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 770

Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort

Ruediger Mueller1, Toni Kaegi1, Axel Finckh2 and Johannes von Kempis1, 1Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 2Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: prognostic factors, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset RA, normal 30-55 years, YORA). Considering that the average age of the population is continuously rising, LORA will gain importance in the near future. Despite this growing importance LORA has not been the focus of much interest in the past. This study was set up to analyse disease activity and progression in LORA in comparison to YORA patients with early disease.

Methods: This is a cohort study within the Swiss RA registry SCQM. We included all patients with recent onset arthritis, either RA (disease duration ≤1 year) or undifferentiated, as diagnosed by the data-entering physician. Patients were followed up to 5 years. The cut off between YORA and LORA was operationally set at 60 years of age. Disease progression and activity was assessed based on DAS 28 and the progression of joint erosions using the Ratingen score.

Results: A total of 592 patients with early undifferentiated or RA was analysed. The age at disease onset had a Gaussian distribution, with a single peak at 60 years of age. 366 patients were 60 years or younger (YORA) and 226 patients were older (LORA) at disease onset. DAS 28 scores were significantly higher among LORA as compared to YORA patients (4.8 vs. 4.5, p = 0.049). Corticosteroids were used in 68% of LORA patients as a first line treatment, compared to 25.4% in YORA patients (X2 test, p < 0.0001). DMARDs, on the other hand, were used in 100% of the YORA patients as first line treatment compared to 91.2% of the LORA patients. During follow up, new glucocorticoid, synthetic, or biologic DMARD were initiated in 32.8%/61.1%/14.1% of all decisions documented among YORA patients and 17.5%/54.6%/6.6% in LORA patients (X2 test, all p < 0.0001. The DAS28 scores decreased in both groups over the observed time period, and the initial differences in disease activity vanished after 1/2 year and during the subsequent follow up. The Ratingen score was higher in LORA than in YORA patients at inclusion (12.7 vs. 5.6, p < 0.0001). The rate of radiological progression at 5 years was similar comparing LORA and YORA (3.3 vs. 2.6, resp., p=0.64). The level of Ratingen scores at onset and during follow up over 5 years did not clearly separate LORA and YORA into two groups), but rather increased linearly when comparing the patients in groups per decade from 20 to 92 years of age.

Conclusion: Our results do not support the existence of a separate LORA subgroup with a distinct peak of incidence and/or course of the disease.


Disclosure:

R. Mueller,
None;

T. Kaegi,
None;

A. Finckh,

Roche, Pfizer, BMS,

2,

Roche, Pfizer, BMS,

5;

J. von Kempis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-late-onset-rheumatoid-arthritis-lora-really-a-distinct-entity-of-ra-results-from-the-swiss-observational-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology